Cargando…
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy...
Autores principales: | Keller, Alana L., Sherbenou, Daniel W., Forsberg, Peter A., Mark, Tomer M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263699/ https://www.ncbi.nlm.nih.gov/pubmed/35814431 http://dx.doi.org/10.3389/fonc.2022.925818 |
Ejemplares similares
-
Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017) -
Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis
por: Lakritz, Stephanie, et al.
Publicado: (2022) -
309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022) -
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021) -
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)